AstraZeneca Plc is to increase its R&D and manufacturing presence in the US with a new investment of $2 billion at multiple sites across the country. Coupled with existing financial commitments, this will deliver total capital of $3.5 billion to the country by the end of 2026. The money will be invested in an R&D centre in Cambridge, Massachusetts; a biologics manufacturing plant in Maryland; specialty manufacturing in Texas; and cell therapy manufacturing at locations on the country’s west and east coasts.
